Darovasertib is under clinical development by Ideaya Biosciences and currently in Phase II for Uveal Melanoma. According to GlobalData, Phase II drugs for Uveal Melanoma have a 20% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Darovasertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Darovasertib (IDE-196) is under development for the treatment of metastatic uveal melanoma, non-small cell lung cancer, Sturge-Weber syndrome and solid tumors including colorectal cancer, pancreatic cancer, hepatocellular carcinoma and cutaneous melanoma. It is administered through oral route as tablet formulation which acts by targeting GNAQ and GNA11 mutated protein kinase C.
Ideaya Biosciences overview
Ideaya Biosciences (Ideaya) is a precision medicine company which develops oncology therapeutics. The company’s lead product candidate IDE196, a protein kinase C (PKC) inhibitor, targets cancers with GNAQ and GNA11 mutations. It develops small molecule inhibitors based on synthetic lethality against known and novel targets. Ideaya also provides solutions for treating tumors with genetic mutations in homologous recombination deficiency(HRD) and high microsatellite instability (MSI). The company collaborates with Novartis Institute for Biomedical Research, Pfizer Inc, Boston Children’s Hospital, Cancer Research UK and, other academic and research institutes for cancer biology, immunology, and small molecule drug discovery. Ideaya is headquartered in South San Francisco, California, the US.
For a complete picture of Darovasertib’s drug-specific PTSR and LoA scores, buy the report here.